Table 1 - Overview of drugs targeting the NP and its pathways

|  |  |  |  |
| --- | --- | --- | --- |
| Drug | Mechanism | Clinical Trials and year | Results on HF symptoms |
| Nestiride | Increasing natriuretic peptide activity | VMAC, 2000 (20)PRECEDENT, 2002 (21)ASCENT-HF, 2009 (22) | Improved BP and dyspneaLess cardiac arrhythmiasMore hypotension |
| Candoxatril | NPi | Uni-centre investigation with only a limited number of patients (23-25) | More exercise toleranceIncrease in vascular resistance |
| Omapatrilat | NPi | IMPRESS, 2000 (26)OVERTURE, 2002 (27)OCTAVE, 2004 (28) | More exercise toleranceIncrease in angioedemaReduction in BPLower mortality |
| LCZ696 | NPi | PARAMOUNT, 2012 (29)PARADIGM, 2014 (30, 31)PARAGON, ongoing (32) | Reduction in BPImproved ejection fractionLower mortalityNo change in angioedema |

Abbreviation: BP: Blood Pressure; NPi: Neprilysin Inhibitors